Key Takeaways Abbott's Q3 adjusted earnings met estimates despite a revenue miss on strong year-over-year growth.Tariffs and weaker Diagnostics sales in China narrowed margins and curbed investor enthusiasm.Diversified growth in Medical Devices and Nutrition supports Abbott's resilience amid trade headwinds.Shares of Abbott (ABT) have edged up 0.7% since the company’s third-quarter 2025 earnings release on Oct. 15, 2025. The company reported a strong year-over-year increase in adjusted earnings and revenues ...